Acknowledgement
This work was supported by Jilin Province Science and Technology Institute of China (Grant No. 20200708072YY).
References
- de Wit E, van Doremalen N, Falzarano D, Munster VJ. 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14: 523-534. https://doi.org/10.1038/nrmicro.2016.81
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273. https://doi.org/10.1038/s41586-020-2012-7
- Yang Y, Islam MS, Wang J, Li Y, Chen X. 2020. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int. J. Biol. Sci. 16: 1708-1717. https://doi.org/10.7150/ijbs.45538
- Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. 2020. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front. Cell. Infect. Microbiol. 10: 587269. https://doi.org/10.3389/fcimb.2020.587269
- Rahimi A, Mirzazadeh A, Tavakolpour S. 2021. Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics 113: 1221-1232. https://doi.org/10.1016/j.ygeno.2020.09.059
- Hu B, Guo H, Zhou P, Shi ZL. 2021. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19: 141-154. https://doi.org/10.1038/s41579-020-00459-7
- Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. 2020. The epidemiology and clinical information about COVID-19. Eur. J. Clin. Microbiol. Infect. Dis. 39: 1011-1019. https://doi.org/10.1007/s10096-020-03874-z
- Soleimanpour S and Yaghoubi A. 2021. COVID-19 vaccine: where are we now and where should we go? Expert Rev. Vaccines 20: 23-44. https://doi.org/10.1080/14760584.2021.1875824
- Izda V, Jeffries MA, Sawalha AH. 2021. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin. Immunol. 222: 108634. https://doi.org/10.1016/j.clim.2020.108634
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020. Safety and efficacy of the BNT162b2 mRNA Covid19 vaccine. New Engl. J. Med. 383: 2603-2615. https://doi.org/10.1056/NEJMoa2034577
- Mahase E. 2020. Covid-19: moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy. BMJ. 371: m4709. https://doi.org/10.1136/bmj.m4709
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586: 589-593. https://doi.org/10.1038/s41586-020-2639-4
- Castells MC, Phillips EJ. 2021. Maintaining safety with SARS-CoV-2 vaccines. New Engl. J. Med. 384: 643-649. https://doi.org/10.1056/NEJMra2035343
- Mahase E. 2021. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ. 372: n86. https://doi.org/10.1136/bmj.n86
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 397: 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
- Knoll MD and Wonodi C. 2021. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet (London, England) 397: 72-74. https://doi.org/10.1016/S0140-6736(20)32623-4
- Hernandez AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. 2021. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol. Rep. 8: 871-879. https://doi.org/10.1016/j.toxrep.2021.04.003
- Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 21: 181-192. https://doi.org/10.1016/S1473-3099(20)30843-4
- Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine development. Expert Rev. Vaccines 9: 1149-1176. https://doi.org/10.1586/erv.10.115
- Li L, Guo P, Zhang X, Yu Z, Zhang W, Sun H. 2021. SARS-CoV-2 vaccine candidates in rapid development. Hum. Vaccin. Immunother. 17: 644-653. https://doi.org/10.1080/21645515.2020.1804777
- Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. 2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499: 102-106. https://doi.org/10.1038/nature12202
- Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, et al. 2020. Nanoparticle vaccines based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53: 1315-30.e9. https://doi.org/10.1016/j.immuni.2020.11.015
- Ghorbani A, Zare F, Sazegari S, Afsharifar A, Eskandari MH, and Pormohammad A. 2020. Development of a novel platform of viruslike particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. New Microbes New Infect. 38: 100786. https://doi.org/10.1016/j.nmni.2020.100786
- Kim C, Kim JD, Seo SU. 2022. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J. Microbiol. 60: 335-346. https://doi.org/10.1007/s12275-022-1608-z
- Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, et al. 2014. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine 32: 2859-2865. https://doi.org/10.1016/j.vaccine.2014.02.025
- Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10: 845-858. https://doi.org/10.1038/nprot.2015.053
- Iserson KV. 2021. SARS-CoV-2 (COVID-19) Vaccine development and production: an ethical way forward. Camb. Q Healthc Ethics 30: 59-68. https://doi.org/10.1017/S096318012000047X
- Yadav T, Srivastava N, Mishra G, Dhama K. 2020. Recombinant vaccines for COVID-19. Hum. Vaccin. Immunother. 16: 2905-2912. https://doi.org/10.1080/21645515.2020.1820808
- He P, Zou Y, and Hu Z. 2015. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccin. Immunother. 11: 477-488. https://doi.org/10.1080/21645515.2014.1004026
- Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. 2020. Establishment and validation of a pseudovirus neutralization assay for SARSCoV-2. Emerg. Microbes Infect. 9: 680-686. https://doi.org/10.1080/22221751.2020.1743767